SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

May 2020 Autoimmune News

Adult Vulvar Lichen Sclerosus: Can Experts Agree on the Assessment of Disease Severity? Standardized descriptions regarding what constitutes mild, moderate, and severe signs and anatomical changes are required before further scale development can occur. PubMed, J Low Genit Tract Dis, 03/20/2020. (Also see Lichen Sclerosus)

Comparative Risk of Cardiovascular Events (MACE) With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Based on meta-analysis, as compared to tumor necrosis factor inhibitors, tocilizumab may be associated with a reduced risk of MACE, whereas csDMARDs may be associated with an increased risk of MACE and stroke. PubMed, Arthritis Care Res (Hoboken), 2020 Apr;72(4):561-576. (Also see DMARDs and Treatments for Rheumatoid Arthritis)

Treatments of osteoporosis increase bone material strength index (BMSi) in patients with low bone mass. In patients at increased fracture risk, antiresorptive treatments induced BMD-independent increases in BMSi values, the magnitude of which depended on pretreatment values. PubMed, Osteoporos Int, 04/08/2020. (Also see Osteoporosis)

Serum levels of soluble programmed cell death protein 1 (sPD1) and soluble programmed cell death protein ligand 2 (sPD-L2)are increased in systemic lupus erythematosus (SLE) and associated with the disease activity. The present study demonstrated the association of serum sPD-1 and sPD-L2 with SLE and suggests their usefulness as disease activity biomarkers for SLE. Sage Journals, Lupus, 04/07/2020. (Also see Systemic Lupus Erythematosus)

Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus (SLE). PC4d+ is associated with vascular events in SLE, independently of traditional and SLE-associated risk factors. PubMed, Rheumatology (Oxford), 04/07/2020. (Also see Symptoms and Complications of Lupus)

Electrodiagnostic Abnormalities Associated with Fibromyalgia. In addition to skin punch biopsies to assess small fiber neuropathy, assessment of the anal reflex may be a useful part of the diagnostic pathway in patients with fibromyalgia. Dovepress, Journal of Pain Research, 04/09/2020. (Also see Fibromyalgia)

Circular Ribonucleic acid (RNA) sequencing indicates circ-IQGAP2 and circ-ZC3H6 as noninvasive biomarkers of primary Sjögren's syndrome (pSS). This study indicated the potential roles of circ-IQGAP2 and circ-ZC3H6 as noninvasive biomarkers for the diagnosis of pSS. PubMed, Rheumatology (Oxford), 04/06/2020. (Also see Diagnosis of Sjögren's Syndrome)

Interleukin-34 as a marker for subclinical proliferative lupus nephritis (LN). Serum IL-34 may be used as a surrogate marker for early renal affection in silent LN, especially the proliferative type. Sage Journals, Lupus, 04/01/2020. (Also see Symptoms and Complications of Lupus and Interleukins)

The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody-associated Vasculitis (AAV). This study longitudinally measured fatigue levels in patients with AAV. PubMed, J Rheumatol, 2020 Apr;47(4):572-579. (Also see Vasculitis)

Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. Just over 5% of patients developed antimalarial retinal complications, over an average of 12.8 years, but no cases were detected in the first 5 years of therapy. PubMed, J Rheumatol, 2020 Apr;47(4):553-556. (Also see Symptoms and Complications of Lupus and DMARDs)

Go to Autoimmune News: April 2020

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.